Zentalis Pharmaceuticals, INC Form 4 insider transactions

David Michael Johnson, a Director at Zentalis Pharmaceuticals, Inc., acquired 57,100 shares of common stock through a grant of restricted stock units.

Zentalis Pharmaceuticals reports a Form 4 filing detailing the acquisition of restricted stock units by Director Jan Skvarka.

Luke Walker, a Director at Zentalis Pharmaceuticals, Inc., acquired 57,100 shares of common stock through a grant of restricted stock units.

Director Enoch Kariuki of Zentalis Pharmaceuticals acquired 57,100 shares of common stock through a grant of restricted stock units.

Zentalis Pharmaceuticals, Inc. reports that Director Scott Myers received 57,100 restricted stock units under the company's Non-Employee Director Compensation Program.

Zentalis Pharmaceuticals, Inc. reports a grant of restricted stock units to Director Shannon Campbell.

Zentalis Pharmaceuticals' Chief Medical Officer, Ingmar Bruns, sold common stock to cover tax withholding obligations from RSU vesting.

Zentalis Pharmaceuticals' PAO and PFO, Vincent Vultaggio, reported sales of common stock totaling 40,224 shares, primarily for tax obligations and a pre-arranged trading plan.

Zentalis Pharmaceuticals CEO Julia Marie Eastland sold shares to cover tax withholding obligations related to restricted stock unit vesting.

Zentalis Pharmaceuticals officer Vincent Vultaggio sold common stock shares in early February 2026, partly to cover tax obligations and partly under a pre-arranged trading plan.

Zentalis Pharmaceuticals' PAO and PFO, Vincent Vultaggio, was granted 100,000 stock options with an exercise price of $2.84.

Zentalis Pharmaceuticals' Chief Legal Officer, James B. Bucher, was granted 100,000 stock options with a $2.84 exercise price, vesting over four years.

Zentalis Pharmaceuticals' Chief Medical Officer, Ingmar Bruns, was granted 365,000 stock options with a strike price of $2.84, vesting over four years.

Zentalis Pharmaceuticals CEO and President Julia Marie Eastland received a grant of 775,000 stock options with an exercise price of $2.84, set to vest over four years.

The Walters Group, a 10% owner and director, acquired over 6.4 million shares of Zentalis Pharmaceuticals common stock in a pre-planned transaction.

Matrix Capital Management, a 10% owner and director, sold 7.5 million shares of Zentalis Pharmaceuticals common stock for $1.33 per share.

Zentalis Pharmaceuticals' Chief Legal Officer, James B. Bucher, acquired 400,000 stock options with an exercise price of $1.54, subject to a four-year vesting schedule.

Zentalis Pharmaceuticals, Inc. Director Luke Nathaniel Walker was granted 57,603 restricted stock units as part of the company's non-employee director compensation program, increasing his beneficial ownership to 144,284 shares.

Zentalis Pharmaceuticals, Inc. Director Jan Skvarka was granted 57,603 restricted stock units as part of the company's non-employee director compensation program.

Zentalis Pharmaceuticals, Inc. Director David Michael Johnson was granted 57,603 restricted stock units (RSUs) as part of the company's non-employee director compensation program.

Zentalis Pharmaceuticals, Inc. Director Enoch Kariuki was granted 57,603 restricted stock units (RSUs) as part of the company's Non-Employee Director Compensation Program, aligning his interests with shareholders.

Zentalis Pharmaceuticals, Inc. Director Scott Dunseth Myers was granted 57,603 restricted stock units as part of the company's non-employee director compensation program.

Director Scott Myers of Zentalis Pharmaceuticals increased his holdings by purchasing 21,000 shares of common stock at $1.3987 per share on April 30, 2025.

Ingmar Bruns, Chief Medical Officer of Zentalis Pharmaceuticals, purchased 20,000 shares of common stock at a price of $2.2828 per share on February 6, 2025.

Vincent Vultaggio, PAO and Interim PFO of Zentalis Pharmaceuticals, reports acquisition and disposal of common stock and stock options on February 3, 2025.

Mark Lackner, Chief Scientific Officer of Zentalis Pharmaceuticals, reports acquisition and disposal of common stock and stock options.

Andrea Paul, Chief Legal Officer of Zentalis Pharmaceuticals, reports acquisition and disposal of common stock and stock options.

Chief Medical Officer of Zentalis Pharmaceuticals, Ingmar Bruns, reports the acquisition of restricted stock units and stock options.

Julia Marie Eastland, CEO and President of Zentalis Pharmaceuticals, reports the acquisition of common stock and stock options.

Director Jan Skvarka of Zentalis Pharmaceuticals, Inc. (ZNTL) acquired 60,000 shares of common stock at a price of $1.7241 per share on January 31, 2025, increasing his total holdings to 149,551 shares.